Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property c...
Partnership combines large-scale real-world imaging and clinical data with advanced AI capabilities to accelerate biomarker development, real-world evi...
First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targe...
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena admini...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment...
BriaCell is advancing a new generation of cancer immunotherapies designed to improve outcomes for patients with metastatic breast cancer and other solid tu...
At ASCO, Dr. Nina Balanchivadze of Sarah Cannon Research Institute at Virginia Oncology Associates and Dr. Kyle Lavin of the UNC School of Medicine shared ...
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared t...
The Alberta Cancer Foundation is investing $35-million to advance cancer clinical trials in Alberta. The amount represents one of the largest investment...
End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming imm...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Diva...
Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company develo...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality...
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, announced that the California Institute for Regenerative Medicine (C...
© 2026 Biopharma Boardroom. All Rights Reserved.
